Format
Sort by
Items per page

Send to

Choose Destination

Search results

Items: 1 to 50 of 507

1.

Predictors of remission in patients with non-radiographic axial spondyloarthritis receiving open-label adalimumab in the ABILITY-3 study.

Sieper J, Landewé R, Magrey M, Anderson JK, Zhong S, Wang X, Lertratanakul A.

RMD Open. 2019 Jun 7;5(1):e000917. doi: 10.1136/rmdopen-2019-000917. eCollection 2019.

2.

Predictors of biologic-free disease control in patients with rheumatoid arthritis after stopping tumor necrosis factor inhibitor treatment.

Ghiti Moghadam M, Lamers-Karnebeek FBG, Vonkeman HE, Ten Klooster PM, Tekstra J, van Schaeybroeck B, Klaasen R, van Onna M, Bernelot Moens HJ, Visser H, Schilder AM, Kok MR, Landewé RBM, van Riel PLCM, van de Laar MAFJ, Jansen TL; Dutch National POET Collaboration.

BMC Rheumatol. 2019 Jun 13;3:3. doi: 10.1186/s41927-019-0071-x. eCollection 2019.

3.

Efficacy and safety of bimekizumab as add-on therapy for rheumatoid arthritis in patients with inadequate response to certolizumab pegol: a proof-of-concept study.

Glatt S, Taylor PC, McInnes IB, Schett G, Landewé R, Baeten D, Ionescu L, Strimenopoulou F, Watling MIL, Shaw S.

Ann Rheum Dis. 2019 Aug;78(8):1033-1040. doi: 10.1136/annrheumdis-2018-214943. Epub 2019 Jun 8.

4.

Spinal radiographic progression over 2 years in ankylosing spondylitis patients treated with secukinumab: a historical cohort comparison.

Braun J, Haibel H, de Hooge M, Landewé R, Rudwaleit M, Fox T, Readie A, Richards HB, Porter B, Martin R, Poddubnyy D, Sieper J, van der Heijde D.

Arthritis Res Ther. 2019 Jun 7;21(1):142. doi: 10.1186/s13075-019-1911-1.

5.

Three handy tips and a practical guide to improve your propensity score models.

Bergstra SA, Sepriano A, Ramiro S, Landewé R.

RMD Open. 2019 May 1;5(1):e000953. doi: 10.1136/rmdopen-2019-000953. eCollection 2019. Review.

6.

Association of seventeen definitions of remission with functional status in a large clinical practice cohort of patients with rheumatoid arthritis.

Carvalho PD, Ferreira RJO, Landewé R, Vega-Morales D, Salomon-Escoto K, Veale DJ, Chopra A, da Silva JAP, Machado PM.

J Rheumatol. 2019 May 1. pii: jrheum.181286. doi: 10.3899/jrheum.181286. [Epub ahead of print]

PMID:
31043552
7.

Is a positive family history of spondyloarthritis relevant for diagnosing axial spondyloarthritis once HLA-B27 status is known?

van Lunteren M, van der Heijde D, Sepriano A, Berg IJ, Dougados M, Gossec L, Jacobsson L, Ramonda R, Rudwaleit M, Sieper J, Landewé R, van Gaalen FA.

Rheumatology (Oxford). 2019 Apr 1. pii: kez095. doi: 10.1093/rheumatology/kez095. [Epub ahead of print]

PMID:
30938446
8.

The development and evaluation of a personalized training in shared decision making skills for rheumatologists.

Mahmood S, Hazes JMW, Veldt P, van Riel P, Landewé R, Bernelot Moens HJ, Pasma A.

J Rheumatol. 2019 Apr 1. pii: jrheum.180780. doi: 10.3899/jrheum.180780. [Epub ahead of print]

PMID:
30936289
9.

Percentage of progressors in imaging: can we ignore regressors?

Sepriano A, Ramiro S, Landewé R, Dougados M, van der Heijde D.

RMD Open. 2019 Feb 26;5(1):e000848. doi: 10.1136/rmdopen-2018-000848. eCollection 2019.

10.

Synovial cellular and molecular signatures stratify clinical response to csDMARD therapy and predict radiographic progression in early rheumatoid arthritis patients.

Humby F, Lewis M, Ramamoorthi N, Hackney JA, Barnes MR, Bombardieri M, Setiadi AF, Kelly S, Bene F, DiCicco M, Riahi S, Rocher V, Ng N, Lazarou I, Hands R, van der Heijde D, Landewé RBM, van der Helm-van Mil A, Cauli A, McInnes I, Buckley CD, Choy EH, Taylor PC, Townsend MJ, Pitzalis C.

Ann Rheum Dis. 2019 Jun;78(6):761-772. doi: 10.1136/annrheumdis-2018-214539. Epub 2019 Mar 16.

11.

Systematic review of rheumatoid arthritis clinical studies: Suboptimal statistical analysis of radiological data.

Mahmood S, van Tuyl L, Schoonmade LJ, Landewé R, van der Heijde D, Twisk J, Boers M.

Semin Arthritis Rheum. 2019 Feb 21. pii: S0049-0172(18)30507-9. doi: 10.1016/j.semarthrit.2019.02.009. [Epub ahead of print] Review.

PMID:
30878153
12.

A Fifty-Two-Week, Randomized, Placebo-Controlled Trial of Certolizumab Pegol in Nonradiographic Axial Spondyloarthritis.

Deodhar A, Gensler LS, Kay J, Maksymowych WP, Haroon N, Landewé R, Rudwaleit M, Hall S, Bauer L, Hoepken B, de Peyrecave N, Kilgallen B, van der Heijde D.

Arthritis Rheumatol. 2019 Jul;71(7):1101-1111. doi: 10.1002/art.40866. Epub 2019 May 28.

PMID:
30848558
13.

Cotreatment with methotrexate in routine care patients with rheumatoid arthritis receiving biological treatment yields better outcomes over time.

Boone NW, Sepriano A, van der Kuy PH, Janknegt R, Peeters R, Landewé RBM.

RMD Open. 2019 Jan 22;5(1):e000836. doi: 10.1136/rmdopen-2018-000836. eCollection 2019.

14.

Individual-level and country-level socioeconomic determinants of disease outcomes in SpA: multinational, cross-sectional study (ASAS-COMOSPA).

Putrik P, Ramiro S, Moltó A, Keszei AP, Norton S, Dougados M, van der Heijde D, Landewé RBM, Boonen A.

Ann Rheum Dis. 2019 Apr;78(4):486-493. doi: 10.1136/annrheumdis-2018-214259. Epub 2019 Jan 23.

PMID:
30674477
15.

Inhibition of radiographic progression in psoriatic arthritis by adalimumab independent of the control of clinical disease activity.

Landewé R, Ritchlin CT, Aletaha D, Zhang Y, Ganz F, Hojnik M, Coates LC.

Rheumatology (Oxford). 2019 Jun 1;58(6):1025-1033. doi: 10.1093/rheumatology/key417.

16.

Response to: 'Catching the falling star: points to consider when using propensity scores' by Ouyang et al.

Bergstra SA, Allaart CF, Landewé RBM.

Ann Rheum Dis. 2018 Dec 30. pii: annrheumdis-2018-214892. doi: 10.1136/annrheumdis-2018-214892. [Epub ahead of print] No abstract available.

PMID:
30598466
17.

Sick leave and its predictors in ankylosing spondylitis: long-term results from the Outcome in Ankylosing Spondylitis International Study.

Webers C, Ramiro S, Landewé R, van der Heijde D, van den Bosch F, Dougados M, van Tubergen A, Boonen A.

RMD Open. 2018 Nov 27;4(2):e000766. doi: 10.1136/rmdopen-2018-000766. eCollection 2018.

18.

Impact of baseline C-reactive protein levels on the response to secukinumab in ankylosing spondylitis: 3-year pooled data from two phase III studies.

Braun J, Deodhar A, Landewé R, Baraliakos X, Miceli-Richard C, Sieper J, Quebe-Fehling E, Martin R, Porter B, Gandhi KK, van der Heijde D; MEASURE 1 and MEASURE 2 study groups.

RMD Open. 2018 Nov 21;4(2):e000749. doi: 10.1136/rmdopen-2018-000749. eCollection 2018.

19.

Is active sacroiliitis on MRI associated with radiographic damage in axial spondyloarthritis? Real-life data from the ASAS and DESIR cohorts.

Sepriano A, Ramiro S, Landewé R, Dougados M, van der Heijde D, Rudwaleit M.

Rheumatology (Oxford). 2018 Dec 12. doi: 10.1093/rheumatology/key387. [Epub ahead of print]

PMID:
30544144
20.

Uncovering the heterogeneity of disease impact in axial spondyloarthritis: bivariate trajectories of disease activity and quality of life.

Imkamp M, Lima Passos V, Boonen A, Arends S, Dougados M, Landewé R, Ramiro S, Van den Bosch F, van der Heijde D, Wink FR, Spoorenberg A, van Tubergen A.

RMD Open. 2018 Nov 14;4(2):e000755. doi: 10.1136/rmdopen-2018-000755. eCollection 2018.

21.

Response to: 'Metering the METEOR in methotrexate failure: is propensity score a falling star?' by Ahmed et al.

Bergstra SA, Allaart CF, Landewé RBM.

Ann Rheum Dis. 2018 Nov 14. pii: annrheumdis-2018-214652. doi: 10.1136/annrheumdis-2018-214652. [Epub ahead of print] No abstract available.

PMID:
30429121
22.

Efficacy and safety of filgotinib, a selective Janus kinase 1 inhibitor, in patients with active ankylosing spondylitis (TORTUGA): results from a randomised, placebo-controlled, phase 2 trial.

van der Heijde D, Baraliakos X, Gensler LS, Maksymowych WP, Tseluyko V, Nadashkevich O, Abi-Saab W, Tasset C, Meuleners L, Besuyen R, Hendrikx T, Mozaffarian N, Liu K, Greer JM, Deodhar A, Landewé R.

Lancet. 2018 Dec 1;392(10162):2378-2387. doi: 10.1016/S0140-6736(18)32463-2. Epub 2018 Oct 22.

23.

Ixekizumab, an interleukin-17A antagonist in the treatment of ankylosing spondylitis or radiographic axial spondyloarthritis in patients previously untreated with biological disease-modifying anti-rheumatic drugs (COAST-V): 16 week results of a phase 3 randomised, double-blind, active-controlled and placebo-controlled trial.

van der Heijde D, Cheng-Chung Wei J, Dougados M, Mease P, Deodhar A, Maksymowych WP, Van den Bosch F, Sieper J, Tomita T, Landewé R, Zhao F, Krishnan E, Adams DH, Pangallo B, Carlier H; COAST-V study group.

Lancet. 2018 Dec 8;392(10163):2441-2451. doi: 10.1016/S0140-6736(18)31946-9. Epub 2018 Oct 22.

PMID:
30360964
24.

How to treat patients with rheumatoid arthritis when methotrexate has failed? The use of a multiple propensity score to adjust for confounding by indication in observational studies.

Bergstra SA, Winchow LL, Murphy E, Chopra A, Salomon-Escoto K, Fonseca JE, Allaart CF, Landewé RBM.

Ann Rheum Dis. 2019 Jan;78(1):25-30. doi: 10.1136/annrheumdis-2018-213731. Epub 2018 Oct 16.

PMID:
30327328
25.

Are gender-specific approaches needed in diagnosing early axial spondyloarthritis? Data from the SPondyloArthritis Caught Early cohort.

Ortolan A, van Lunteren M, Ramiro S, Ramonda R, Landewé RBM, Dagfinrud H, Jacobsson LTH, van der Heijde D, van Gaalen FA.

Arthritis Res Ther. 2018 Oct 1;20(1):218. doi: 10.1186/s13075-018-1705-x.

26.

Validation and reliability of translation of the ASAS Health Index in a Colombian Spanish-speaking population with spondyloarthritis.

Bautista-Molano W, Landewé RBM, Kiltz U, Valle-Oñate R, van der Heijde D.

Clin Rheumatol. 2018 Nov;37(11):3063-3068. doi: 10.1007/s10067-018-4308-7. Epub 2018 Sep 26.

PMID:
30259248
27.

A single determination of C-reactive protein does not suffice to declare a patient with a diagnosis of axial spondyloarthritis 'CRP-negative'.

Landewé R, Nurminen T, Davies O, Baeten D.

Arthritis Res Ther. 2018 Sep 14;20(1):209. doi: 10.1186/s13075-018-1707-8.

28.

Is it Useful to Repeat Magnetic Resonance Imaging of the Sacroiliac Joints After Three Months or One Year in the Diagnosis of Patients With Chronic Back Pain and Suspected Axial Spondyloarthritis?

Bakker PAC, Ramiro S, Ez-Zaitouni Z, van Lunteren M, Berg IJ, Landewé R, Ramonda R, van Oosterhout M, Reijnierse M, van Gaalen FA, van der Heijde D.

Arthritis Rheumatol. 2019 Mar;71(3):382-391. doi: 10.1002/art.40718. Epub 2019 Feb 6.

29.

Response to: 'Dual target strategy: a proposal to mitigate the risk of overtreatment and enhance patient satisfaction in rheumatoid arthritis' by Ferreira et al.

Landewé RBM.

Ann Rheum Dis. 2018 Aug 20. pii: annrheumdis-2018-214221. doi: 10.1136/annrheumdis-2018-214221. [Epub ahead of print] No abstract available.

PMID:
30127057
30.

Response to: 'Early identification of rheumatoid arthritis; the risk of overtreatment in perspective' by Landewé.

Landewé RBM.

Ann Rheum Dis. 2018 Aug 10. pii: annrheumdis-2018-214172. doi: 10.1136/annrheumdis-2018-214172. [Epub ahead of print] No abstract available.

PMID:
30097455
31.

Induction of sustained remission in early inflammatory arthritis with the combination of infliximab plus methotrexate: the DINORA trial.

Stamm TA, Machold KP, Aletaha D, Alasti F, Lipsky P, Pisetsky D, Landewe R, van der Heijde D, Sepriano A, Aringer M, Boumpas D, Burmester G, Cutolo M, Ebner W, Graninger W, Huizinga T, Schett G, Schulze-Koops H, Tak PP, Martin-Mola E, Breedveld F, Smolen J.

Arthritis Res Ther. 2018 Aug 9;20(1):174. doi: 10.1186/s13075-018-1667-z.

32.
33.

Depressive mood and low social support are not associated with arthritis development in patients with seropositive arthralgia, although they predict increased musculoskeletal symptoms.

Holla JFM, van Beers-Tas MH, van de Stadt LA, Landewé R, Twisk JWR, Dekker J, van Schaardenburg D.

RMD Open. 2018 Jun 27;4(1):e000653. doi: 10.1136/rmdopen-2018-000653. eCollection 2018.

34.

Inequity in access to bDMARD care and how it influences disease outcomes across countries worldwide: results from the METEOR-registry.

Bergstra SA, Branco JC, Vega-Morales D, Salomon-Escoto K, Govind N, Allaart CF, Landewé RBM.

Ann Rheum Dis. 2018 Oct;77(10):1413-1420. doi: 10.1136/annrheumdis-2018-213289. Epub 2018 Jul 6.

PMID:
29980576
35.

Overdiagnosis and overtreatment in rheumatology: a little caution is in order.

Landewé RBM.

Ann Rheum Dis. 2018 Oct;77(10):1394-1396. doi: 10.1136/annrheumdis-2018-213700. Epub 2018 Jul 4. Review.

PMID:
29973350
36.

Frequency of Impaired Spinal Mobility in Patients with Chronic Back Pain Compared to Patients with Early Axial Spondyloarthritis.

Fongen C, Dagfinrud H, Berg IJ, Ramiro S, van Gaalen F, Landewé R, Ramonda R, van der Heijde D, Fagerli KM.

J Rheumatol. 2018 Dec;45(12):1643-1650. doi: 10.3899/jrheum.170786. Epub 2018 Jul 1.

PMID:
29961689
37.

Efficacy and safety of continuing versus withdrawing adalimumab therapy in maintaining remission in patients with non-radiographic axial spondyloarthritis (ABILITY-3): a multicentre, randomised, double-blind study.

Landewé R, Sieper J, Mease P, Inman RD, Lambert RG, Deodhar A, Marzo-Ortega H, Magrey M, Kiltz U, Wang X, Li M, Zhong S, Mostafa NM, Lertratanakul A, Pangan AL, Anderson JK.

Lancet. 2018 Jul 14;392(10142):134-144. doi: 10.1016/S0140-6736(18)31362-X. Epub 2018 Jun 29.

PMID:
29961640
38.

Sex-associated Treatment Differences and Their Outcomes in Rheumatoid Arthritis: Results from the METEOR Register.

Bergstra SA, Allaart CF, Ramiro S, Chopra A, Govind N, Silva C, Murphy EA, Landewé RBM.

J Rheumatol. 2018 Oct;45(10):1361-1366. doi: 10.3899/jrheum.171176. Epub 2018 Jun 15.

PMID:
29907672
39.

Modified stoke ankylosing spondylitis spinal score as an outcome measure to assess the impact of treatment on structural progression in ankylosing spondylitis.

van der Heijde D, Braun J, Deodhar A, Baraliakos X, Landewé R, Richards HB, Porter B, Readie A.

Rheumatology (Oxford). 2019 Mar 1;58(3):388-400. doi: 10.1093/rheumatology/key128.

40.

Work participation in spondyloarthritis across countries: analysis from the ASAS-COMOSPA study.

Rodrigues Manica S, Sepriano A, Ramiro S, Pimentel Santos F, Putrik P, Nikiphorou E, Norton S, Molto A, Dougados M, van der Heijde D, Landewé RBM, van den Bosch FE, Boonen A.

Ann Rheum Dis. 2018 Sep;77(9):1303-1310. doi: 10.1136/annrheumdis-2018-213464. Epub 2018 Jun 2.

PMID:
29860232
41.

Multi-biomarker disease activity score as a predictor of disease relapse in patients with rheumatoid arthritis stopping TNF inhibitor treatment.

Ghiti Moghadam M, Lamers-Karnebeek FBG, Vonkeman HE, Ten Klooster PM, Tekstra J, Schilder AM, Visser H, Sasso EH, Chernoff D, Lems WF, van Schaardenburg DJ, Landewe R, Bernelot Moens HJ, Radstake TRDJ, van Riel PLCM, van de Laar MAFJ, Jansen TL; Dutch National POET Collaboration.

PLoS One. 2018 May 23;13(5):e0192425. doi: 10.1371/journal.pone.0192425. eCollection 2018.

42.

Are globals for health, well-being and quality of life interchangeable? A mixed methods study in ankylosing spondylitis patients and controls.

van Tubergen A, Gulpen A, Landewé R, Boonen A.

Rheumatology (Oxford). 2018 Sep 1;57(9):1555-1562. doi: 10.1093/rheumatology/key129.

PMID:
29788458
43.

Is radiographic progression in radiographic axial spondyloarthritis related to matrix metalloproteinase degradation of extracellular matrix?

Siebuhr AS, van der Heijde D, Bay-Jensen AC, Karsdal MA, Landewé R, van Tubergen A, Ramiro S.

RMD Open. 2018 May 14;4(1):e000648. doi: 10.1136/rmdopen-2018-000648. eCollection 2018.

44.

An Economic Evaluation of Stopping Versus Continuing Tumor Necrosis Factor Inhibitor Treatment in Rheumatoid Arthritis Patients With Disease Remission or Low Disease Activity: Results From a Pragmatic Open-Label Trial.

Tran-Duy A, Ghiti Moghadam M, Oude Voshaar MAH, Vonkeman HE, Boonen A, Clarke P, McColl G, Ten Klooster PM, Zijlstra TR, Lems WF, Riyazi N, Griep EN, Hazes JMW, Landewé R, Bernelot Moens HJ, van Riel PLCM, van de Laar MAFJ, Jansen TL; Dutch National POET Collaboration.

Arthritis Rheumatol. 2018 Oct;70(10):1557-1564. doi: 10.1002/art.40546. Epub 2018 Aug 23.

PMID:
29745059
45.

"Big Data" in Rheumatology: Intelligent Data Modeling Improves the Quality of Imaging Data.

Landewé RBM, van der Heijde D.

Rheum Dis Clin North Am. 2018 May;44(2):307-315. doi: 10.1016/j.rdc.2018.01.007. Review.

PMID:
29622297
46.

The Impact of Illness Perceptions and Coping on the Association Between Back Pain and Health Outcomes in Patients Suspected of Having Axial Spondyloarthritis: Data From the SPondyloArthritis Caught Early Cohort.

van Lunteren M, Scharloo M, Ez-Zaitouni Z, de Koning A, Landewé R, Fongen C, Ramonda R, Kaptein AA, van Gaalen FA, van der Heijde D.

Arthritis Care Res (Hoboken). 2018 Dec;70(12):1829-1839. doi: 10.1002/acr.23566.

47.

Impact of replacing radiographic sacroiliitis by magnetic resonance imaging structural lesions on the classification of patients with axial spondyloarthritis.

Bakker PA, van den Berg R, Hooge M, van Lunteren M, Ez-Zaitouni Z, Fagerli KM, Landewé R, van Oosterhout M, Ramonda R, Reijnierse M, van Gaalen FA, van der Heijde D.

Rheumatology (Oxford). 2018 Mar 23. doi: 10.1093/rheumatology/kex532. [Epub ahead of print]

PMID:
29584927
48.

Imaging of the sacroiliac joints is important for diagnosing early axial spondyloarthritis but not all-decisive.

Ez-Zaitouni Z, Landewé R, van Lunteren M, Bakker PA, Fagerli KM, Ramonda R, Jacobsson LTH, van der Heijde D, van Gaalen FA.

Rheumatology (Oxford). 2018 Mar 20. doi: 10.1093/rheumatology/key035. [Epub ahead of print]

PMID:
29579265
49.

Secukinumab improves active psoriatic arthritis symptoms and inhibits radiographic progression: primary results from the randomised, double-blind, phase III FUTURE 5 study.

Mease P, van der Heijde D, Landewé R, Mpofu S, Rahman P, Tahir H, Singhal A, Boettcher E, Navarra S, Meiser K, Readie A, Pricop L, Abrams K.

Ann Rheum Dis. 2018 Jun;77(6):890-897. doi: 10.1136/annrheumdis-2017-212687. Epub 2018 Mar 17.

50.

In Early Axial Spondyloarthritis, Increasing Disease Activity Is Associated with Worsening of Health-related Quality of Life over Time.

van Lunteren M, Ez-Zaitouni Z, de Koning A, Dagfinrud H, Ramonda R, Jacobsson L, Landewé R, van der Heijde D, van Gaalen FA.

J Rheumatol. 2018 Jun;45(6):779-784. doi: 10.3899/jrheum.170796. Epub 2018 Mar 15.

PMID:
29545448

Supplemental Content

Loading ...
Support Center